322 related articles for article (PubMed ID: 27787547)
1. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Haas NB; Manola J; Dutcher JP; Flaherty KT; Uzzo RG; Atkins MB; DiPaola RS; Choueiri TK
JAMA Oncol; 2017 Sep; 3(9):1249-1252. PubMed ID: 28278333
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Lancet; 2023 Mar; 401(10379):821-832. PubMed ID: 36774933
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
[TBL] [Abstract][Full Text] [Related]
6. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma.
Muselaers CH; Boers-Sonderen MJ; van Oostenbrugge TJ; Boerman OC; Desar IM; Stillebroer AB; Mulder SF; van Herpen CM; Langenhuijsen JF; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2016 May; 69(5):767-70. PubMed ID: 26706103
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
10. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
12. Positron Emission Tomography/Computed Tomography with
Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
[TBL] [Abstract][Full Text] [Related]
13. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.
Eisen T; Frangou E; Oza B; Ritchie AWS; Smith B; Kaplan R; Davis ID; Stockler MR; Albiges L; Escudier B; Larkin J; Bex A; Joniau S; Hancock B; Hermann GG; Bellmunt J; Hodgkinson E; Stewart GD; Barber J; Brown J; McMenemin R; Nathan P; Pickering LM; Parmar MKB; Meade A
J Clin Oncol; 2020 Dec; 38(34):4064-4075. PubMed ID: 33052759
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Gurney H; Chevreau C; Melichar B; Kopyltsov E; Alva A; Burke JM; Doshi G; Topart D; Oudard S; Hammers H; Kitamura H; Bedke J; Perini RF; Zhang P; Imai K; Willemann-Rogerio J; Quinn DI; Powles T;
N Engl J Med; 2021 Aug; 385(8):683-694. PubMed ID: 34407342
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial.
Chamie K; Klöpfer P; Bevan P; Störkel S; Said J; Fall B; Belldegrun AS; Pantuck AJ
Urol Oncol; 2015 May; 33(5):204.e25-33. PubMed ID: 25823535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
